Depression - Articles - Page 16

When Further Medication Trials Seem Futile

June 10, 2020

Joseph Goldberg, MD

Dr. Goldberg is a clinical professor of psychiatry at the Mount Sinai School of Medicine and maintains a private practice focused on mood disorders. He has published three psychiatric textbooks and is completing a fourth on psychopharmacology. Dr. Goldberg has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Joe Goldberg believes we do a disservice by shuffling patients through medication trials that have little chance of working. He shares techniques to engage patients, motivate change, combat demoralization, as well as his top pharmacologic strategies for highly resistant depression.

How Effective is Esketamine [60 Sec Psych]

May 16, 2020

It's been a year since esketamine's (Spravato) debut for treatment resistant depression, and the numbers are in: to treat and to harm. A review of Citrome L, DiBernardo A, Singh J. 144 Esketamine Nasal Spray for Management of Treatment-Resistant Depression: Number Needed to Treat, Number Needed to Harm, Likelihood to...

What Cocaine Tells Us About Depression [60 Sec Psych]

May 13, 2020

Depressed patients who've used cocaine in the past might be more likely to develop bipolar disorder. A review of de Azevedo Cardoso T, Jansen K, Mondin TC, et al. Lifetime cocaine use is a potential predictor for conversion from major depressive disorder to bipolar disorder: a prospective study. Psychiatry Clin...

Trazodone: The Forgotten Antidepressant

May 7, 2020

Eugene Rubin, MD

Eugene Rubin, MD Private practice, Bingham Farms, MI. Dr. Rubin has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Trazodone is rarely used as an antidepressant, and that’s a missed opportunity. It lacks the weight gain, sleep disruption, and sexual side effects that so many antidepressants cause. In this article are two important dosing tips that can make it work better.

The Psychopharmacology Algorithm Project

March 30, 2020

David Osser, MD

David Osser, MD

General Editor of the Psychopharmacology Algorithm Project at the Harvard South Shore Psychiatry Residency Training Program and Associate Professor of Psychiatry at Harvard University. Dr. Osser has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Dr. Osser set out to develop a psychopharmacology algorithm that actually changes practice. He speaks to us on antidepressants in bipolar, psychoses that don’t need antipsychotics, and his top picks for bipolar mania, bipolar depression, and unipolar depression.

Top Lifestyle Tips for Depression and Bipolar

March 16, 2020

How do you make the most of brief therapy during a medication visit? Chris Aiken, MD, pulls a few of his favorite interventions from his new book, The Depression and Bipolar Workbook.Date Published: 3/16/20Duration: 20 minutes 24 seconds...

Optimal Antidepressant Doses in Major Depression

March 9, 2020

Kristen Gardner, PharmD.

Kristen Gardner, PharmD. Dr. Gardner has disclosed that she has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

More is not necessarily better in psychopharmacology. Some medications have plateau effect, while others follow a “U-shaped curve,” causing more problems as the dose goes too high. This metaanalysis looked at 77 dose-response trials with antidepressants to quantify their optimal therapeutic window.

EXPERT Q&A

Inflammatory Biomarkers in Depression

February 10, 2020

Andrew H. Miller, MD

Andrew H. Miller, MD

William P. Timmie Professor of Psychiatry and Behavioral Sciences, Emory University, GA Dr. Miller has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Andrew Miller, Vice Chair of Psychiatry Research at Emory University, translates two decades research on inflammation and depression into practical terms, including a low-cost biomarker that may guide antidepressant selection.

How to Use Pramipexole

February 10, 2020

Pramipexole is a selective agonist at the dopamine D3 receptor, which is thought to regulate hedonic drive. It is FDA approved in Parkinson’s disease and restless legs syndrome, and has five randomized controlled trials in depression.